Core Insights - Cytek Biosciences reported strong revenue growth in Q4 2025, with total revenue reaching $62.1 million, an 8% increase compared to Q4 2024, driven by robust FSP instrument sales and recurring revenue streams [3][4][8] - The company aims to focus on high-margin recurring revenue growth, instrument adoption, innovative product pipeline advancement, and sustainable growth in the cell analysis market for 2026 [3] Financial Performance - Q4 2025 total revenue was $62.1 million, marking an 8% increase from Q4 2024, the highest quarterly revenue in the company's history [4][8] - Full year 2025 total revenue was $201.5 million, a 1% increase compared to 2024, with recurring revenue growing 21% to account for 34% of total revenue [8][13] - GAAP gross profit for Q4 2025 was $32.9 million, a 2% decrease from Q4 2024, with a gross profit margin of 53% [5][8] - Operating expenses for Q4 2025 were $38.5 million, a 25.5% increase from Q4 2024, primarily due to higher general and administrative and sales and marketing expenses [6][9] - The company reported a net loss of $44.1 million in Q4 2025, compared to a net income of $9.6 million in Q4 2024, largely due to a non-cash valuation allowance against deferred tax assets [10][18] Operational Highlights - Cytek expanded its installed base to 3,664 instruments, with 630 new placements in 2025, and saw a 22% increase in unit placements of the Aurora CS system [8] - The company launched the Cytek Aurora™ Evo system and the Cytek MuseMicro cell analyzer, the latter winning the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year [8] Future Outlook - For 2026, Cytek projects revenue in the range of $205 million to $212 million, representing a growth of 2% to 5% over 2025 [21]

Core Insights - Cytek Biosciences reported a total revenue of $45.6 million for Q2 2025, reflecting a 2% decrease compared to Q2 2024, primarily due to lower product revenue in EMEA and APAC regions, although service revenue showed growth globally and in the U.S. [5][10] - The company launched the Cytek Aurora Evo system, which is expected to enhance the adoption of its solutions and strengthen its market position [3][10] - Cytek's total recurring revenue, which includes service and reagent revenues, grew by 16% year-over-year, accounting for 32% of the total revenue over the last 12 months [10] Financial Performance - GAAP gross profit for Q2 2025 was $23.9 million, a 6% decrease from Q2 2024, with a gross profit margin of 52% compared to 55% in the previous year [6][10] - Operating expenses increased by 2% to $34.5 million, with R&D expenses decreasing by 12% to $8.8 million, while general and administrative expenses rose by 16% to $13.5 million [7][8] - The net loss for Q2 2025 was $5.6 million, an improvement from a net loss of $10.4 million in Q2 2024 [8][10] Market Outlook - The company narrowed its 2025 revenue guidance to a range of $196 million to $205 million, indicating a potential growth of -2% to +2% compared to 2024 [12] - Cytek aims to expand its installed base globally and enhance recurring revenue through its service and reagent businesses, while focusing on innovation to redefine industry standards [4][10]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q2 2025 on August 6, 2025, followed by a conference call to discuss the results and business outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2]. - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents, software, and services [2]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3]. Information Distribution - The company utilizes its website, LinkedIn, and X (formerly Twitter) for distributing material information and compliance with disclosure obligations under Regulation FD [4].